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a comparison of the manufacturer’s
reference range and laboratory healthy
volunteer results to patients with
rheumatoid arthritis
Gillian Wheater1*, Mohsen Elshahaly2, Stephen P Tuck2,3, John Drury1, Jaap M van Laar2,3
From Northern and Yorkshire Deaneries Annual Rheumatology Conference
York, UK. 26 September 2012
Background
Biochemical markers of bone turnover have been used
in research for a long time and are now being recog-
nised as helpful tools in the clinical management of
bone disease. It is important to establish robust refer-
ence values for the interpretation of these markers. In
addition to standardising pre-analytical variability it is
unclear whether manufacturer’s ranges take into account
global differences between subjects and so each labora-
tory should investigate the transferability of the expected
values to its own patient population and if necessary
determine its own reference ranges.
Materials and methods
Serum samples from 70 healthy volunteers were ana-
lysed for biochemical markers of bone formation (pro-
collagen type I amino-terminal propeptide [P1NP] and
osteocalcin [OC]) and bone resorption (beta carboxy-
terminal cross-linking telopeptide of bone collagen
[bCTX] on the Roche Elecsys 2010. The results were
compared to the manufacturer’s reference range and to
46 samples from patients with severe refractory rheuma-
toid arthritis prior to treatment with rituximab.
Results
We found substantial inter-person variability in all of
the biomarkers and differences between the manufac-
turer and healthy control ranges (Table 1).
Conclusions
These results demonstrate the large between-person
variability in serum bone markers and the differences
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Table 1 Comparison of bone marker results between manufacturer, healthy controls and rheumatoid arthritis patients
Manufacturer Healthy controls Rheumatoid arthritis
Prec Postd Male Prec Postd Male Prec Postd Male
bCTXa
ng/L
299
±274
556
±452
300
±284
192
±196
199
±264
325
±382
139
±184
354
±572
337
±410
P1NPb
µg/L
27.8
15-59
37.1
16-74
No data 31.9
22-58
32.6
18-66
51.5
22-79
30.1
11-50
39.1
12-73
40.5
13-81
OCb
µg/L
23.0
11-43
27.0
15-46
25.0
14-42
14.9
11-26
15.3
10-22
20.2
14-36
12.4
5-21
15.3
6-40
19.6
4-42
a mean ± 2 standard deviations (as reported by manufacturer); b median plus interquartile range (as reported by manufacturer); c pre-menopausal female;
d post-menopausal female
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between defined ‘healthy control’ ranges, this can be
critical when assessing patients with bone disease. We
suggest that it is therefore important for each laboratory
to investigate the transferability of the quoted reference
range to its own patient population based on equivalent
standardised collection conditions, and where necessary
determine its own ranges. We recognize that it is often
difficult to recruit sufficient healthy volunteers but the
widespread availability of automated bone marker assays
now means that harmonisation of methods and specific
reference ranges may be possible using well-characterised
populations in larger cohorts.
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